As GLP-1 obesity drugs capture the imagination of global healthcare investors, savvy hedge funds are scouting for the next breakthrough story. The latest 13F filings reveal that BVF, a prominent biotech-focused hedge fund, significantly expanded its position in Structure Therapeutics (NASDAQ: GPCR) during the fourth quarter, acquiring more than 275,000 shares in an estimated $11.2 million transaction.
As of February 17, 2026, BVF’s stake in GPCR had swelled to $242 million, representing 8.1% of the fund’s reported 13F assets under management. The position now stands alongside other concentrated biotech bets including Kymera Therapeutics and Revolution Medicines as core holdings in BVF’s portfolio.
The disclosure has reignited interest in the oral obesity drug race and thrust Structure Therapeutics—a clinical-stage biopharmaceutical company—into the spotlight. GPCR shares have climbed 214.3% over the past twelve months, dramatically outperforming the S&P 500, and now command a market capitalization of approximately $4.1 billion.
According to a Securities and Exchange Commission filing dated February 17, 2026, BVF purchased 275,105 shares of Structure Therapeutics at an estimated average price of $40.7 per share during the quarter, representing total inflows of roughly $11.2 million. With GPCR closing at $71.41 on February 17, the fund’s latest addition has already generated a paper gain exceeding 75% in a matter of weeks.
Looking at the longer arc, GPCR has staged a remarkable rally from $22.7 one year ago, touching a high of $82 along the way—a testament to growing investor enthusiasm around its pipeline.
Following BVF’s accumulation, the fund’s total GPCR position surged by $152.3 million from the previous filing’s $89.7 million, a figure that captures both active buying and price appreciation. The holding now accounts for 8.1% of BVF’s portfolio, signaling its conviction in the obesity drug developer.
Structure Therapeutics is a clinical-stage biopharmaceutical company specializing in oral small molecule therapeutics for chronic diseases with significant unmet medical need. Its lead candidate, aleniglipron (formerly GSBR-1290), targets type 2 diabetes and obesity, while earlier-stage pipeline assets address pulmonary and cardiovascular disorders.
The company leverages deep expertise in G-protein-coupled receptor (GPCR) biology to develop differentiated oral therapies aimed at large patient populations underserved by current treatment options. Like many clinical-stage biotechs, Structure remains in investment mode, reporting a net loss of $210.7 million over the trailing twelve months with no product revenue to date.
In the current obesity drug landscape, Novo Nordisk and Eli Lilly dominate with injectable GLP-1 therapies. But market consensus increasingly points to oral formulations as the next major growth frontier—and Structure Therapeutics is positioning itself as a formidable contender.
BVF’s accumulation of GPCR shares represents a significant vote of confidence from one of biotech’s most respected specialist funds. In the high-stakes obesity market—where oral formulations could disrupt the existing order—Structure Therapeutics combines promising data, a clear development pathway, and ample capital to execute.
Yet for retail investors, the calculus requires balancing optimism with discipline. The stock’s 214% rally already prices in considerable optimism around aleniglipron’s prospects. The upcoming Phase 3 readout will serve as the critical catalyst, while progress in the oral amylin program bears watching as a potential pipeline driver.
As BVF’s position demonstrates, this is a game of science, timing, and capital allocation—where the rewards for successful bets could be substantial, but the risks of failure remain real. For now, Structure Therapeutics has secured a place among the most closely watched players in the race to reshape obesity treatment.
